LitAlert ~~ GeneLit.com

    • The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women.
    • Larionov A, Fewings E, Redman J, Goldgraben M, Clark G, Boice J, Concannon P, Bernstein J, Conti DV, the WECARE Study Collaborative Group, Tischkowitz M.
    • Cancers (Basel). 2023 Jan 8;15(2):415. doi: 10.3390/cancers15020415.

    • High-dose chemotherapy with stem cell rescue to treat stage III homologous deficient breast cancer: factors influencing clinical implementation.
    • Verbeek JGE, de Jong VMT, Wijnja HM, Jager A, Linn SC, Retèl VP, van Harten WH.
    • BMC Cancer. 2023 Jan 7;23(1):26. doi: 10.1186/s12885-022-10412-x.

    • Role of HIPEC after Complete Cytoreductive Surgery (CRS) in Peritoneal Recurrence of Platinum-Sensitive Recurrent Ovarian Cancer (OC): The Aim for Standardization at Two Reference Centers for CRS.
    • cs M, Gerken M, Schmitt V, Piso P, Alfred Königsrainer A, Baransi S, Yurttas C, Häusler S, Horvath P.
    • Cancers (Basel). 2023 Jan 7;15(2):405. doi: 10.3390/cancers15020405.

    • Diagnostic and Therapeutic Pathway of Advanced Ovarian Cancer with Peritoneal Metastases.
    • Ghirardi V, Fagotti A, Ansaloni L, Valle M, Roviello F, Sorrentino L, Accarpio F, Baiocchi G, Piccini L, De Simone M, Coccolini F, Visaloco M, Bacchetti S, Scambia G, Marrelli D.
    • Cancers (Basel). 2023 Jan 7;15(2):407. doi: 10.3390/cancers15020407.

    • Clinical application of PARP inhibitors in ovarian cancer: from molecular mechanisms to the current status.
    • Wu Y, Xu S, Cheng S, Yang J, Wang Y.
    • J Ovarian Res. 2023 Jan 7;16(1):6. doi: 10.1186/s13048-023-01094-5.

    • Missed opportunities in the real-world genetic testing in BRCA gene variant carriers with cancers meeting NCCN criteria.
    • Lee SS, Rajeev P, Finning S, Oh C, Pothuri B.
    • Gynecol Oncol. 2023 Jan 5;170:32-37. doi: 10.1016/j.ygyno.2022.12.015. Epub ahead of print.